Ischemia

Study Provides New Tool to Assess Amputation Risk Following Popliteal Vascular Injury

Wednesday, September 22, 2021 - 12:40pm

OBanion states, The aim of the present study, unlike the older systems, was to provide an easy to use scoring system that could be used to preoperatively and effectively risk stratify patients with traumatic popliteal vascular injuries for major amputation.

Key Points: 
  • OBanion states, The aim of the present study, unlike the older systems, was to provide an easy to use scoring system that could be used to preoperatively and effectively risk stratify patients with traumatic popliteal vascular injuries for major amputation.
  • This study confirms that patients with popliteal vascular injuries are at significant risk for amputation.
  • The POPSAVEIT tool is a valuable tool to assess this risk as soon as the patient enters the emergency room.
  • The Society for Vascular Surgery is the leading not-for-profit, professional medical society on establishing causes and treatments for vascular disease.

Restoring Lives: 2021 Heart of Case Management Awards

Wednesday, September 22, 2021 - 12:01pm

These skills were evident in the nominations received for the 6th annual Heart of Case Management Award, which was expanded this year to include hundreds of Coventry case managers as well.

Key Points: 
  • These skills were evident in the nominations received for the 6th annual Heart of Case Management Award, which was expanded this year to include hundreds of Coventry case managers as well.
  • The Genex Heart of Case Management Award recognizes seven case managers who have made the greatest impact on the injured employees they served.
  • Debbi Gillespie took over case management responsibilities four months after, due to her catastrophic case management expertise.
  • Genex telephonic case manager Tammy Zivic was assigned to the case, promptly making contact with the injured employee.

Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF

Tuesday, September 21, 2021 - 2:45pm

TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that AdvisorShares Investments LLC (AdvisorShares), a leading sponsor of actively managed exchange-traded funds (ETFs) has included Revive Therapeutics in the inaugural launch of its AdvisorShares Psychedelics ETF (PSIL).

Key Points: 
  • TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive or the Company) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that AdvisorShares Investments LLC (AdvisorShares), a leading sponsor of actively managed exchange-traded funds (ETFs) has included Revive Therapeutics in the inaugural launch of its AdvisorShares Psychedelics ETF (PSIL).
  • PSIL invests in the emerging psychedelic drugs sector, offering exposure to biotechnology, pharmaceutical, and life sciences companies leading the way in this nascent industry.
  • The ETF at launch includes 16 publicly listed companies offering investors exposure to companies who are leading the way in the emerging psychedelics space.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke

Monday, September 13, 2021 - 1:32pm

The ReMEDy2 Trial is a randomized, double-blind, placebo-controlled Phase 2/3 adaptive trial designed to enroll 350 patients at 75 sites in the United States.

Key Points: 
  • The ReMEDy2 Trial is a randomized, double-blind, placebo-controlled Phase 2/3 adaptive trial designed to enroll 350 patients at 75 sites in the United States.
  • DM199 is currently being studied in patients with acute ischemic stroke and chronic kidney disease.
  • DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.
  • DiaMedicas lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease.

BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada

Thursday, September 9, 2021 - 1:30pm

RALEIGH, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.

Key Points: 
  • ELYXYB is the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.
  • ELYXYBs unit-dose oral solution makes it convenient for patients to take it immediately upon emergence of acute migraine attacks.
  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.
  • ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

Wednesday, September 8, 2021 - 9:00am

Following assessment of the interim efficacy and safety data, the independent Data Monitoring Committee (DMC) recommended continuation of the trial unchanged.

Key Points: 
  • Following assessment of the interim efficacy and safety data, the independent Data Monitoring Committee (DMC) recommended continuation of the trial unchanged.
  • The Phase 3 trial with REX-001 includes two planned interim analyses after 30% and 50% of patients enrolled have reached the 12-month follow-up visit.
  • We are delighted with the positive outcome in this interim analysis of the Phase 3 trial for REX-001 in CLTI.
  • The positive interim analysis confirms the potential of REX-001 as an effective treatment of the disease, commented Joe Dupere, CEO at Ixaka
    This first Phase 3 interim analysis is a critical milestone for our lead cell therapy candidate REX-001.

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

Monday, September 6, 2021 - 6:59am

Peijia Medical was founded in 2012 and its headquarter is based in Suzhou, Jiangsu Province, China. It was listed on the Hong Kong Stock Exchange in May 2020. With "Devotion to the Heart, Reverence for Life" as its vision, Peijia Medical always puts life and safety in the first place, striving to maintain human life and health from its years of exploration in technology and its innovative persistence. Peijia Medical's strategic layout can be summarized as the "Innovation-oriented, Simultaneous Treatment of Cardiovascular and Cerebrovascular Diseases". It is dedicated to the innovation, R&D and production of high-end medical devices for structural heart disease and cerebrovascular interventions--covering aortic valve, mitral valve, tricuspid valve, surgical accessories, and diseases related to hemorrhage, ischemia and pathways in cerebrovascular intervention. It has built a relatively comprehensive array of product and solution portfolios in the field of structural heart disease and cerebrovascular interventions for use throughout China.

Key Points: 
  • Dr. Kar currently serves as the Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Health System, and Professor of Medicine at the David Geffen School of Medicine at UCLA.
  • He is recognized as the leading physician in developing and implementing minimally-invasive techniques in structural heart disease interventions.
  • Dr. Kar receives research grants from and is a consultant to multinational companies, such as Boston Scientific Corporation, Gore & Associates, and Abbott Vascular.
  • Peijia Medical was founded in 2012 and its headquarter is based in Suzhou,Jiangsu Province,China.

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

Monday, September 6, 2021 - 6:44am

Peijia Medical was founded in 2012 and its headquarter is based in Suzhou, Jiangsu Province, China. It was listed on the Hong Kong Stock Exchange in May 2020. With "Devotion to the Heart, Reverence for Life" as its vision, Peijia Medical always puts life and safety in the first place, striving to maintain human life and health from its years of exploration in technology and its innovative persistence. Peijia Medical's strategic layout can be summarized as the "Innovation-oriented, Simultaneous Treatment of Cardiovascular and Cerebrovascular Diseases". It is dedicated to the innovation, R&D and production of high-end medical devices for structural heart disease and cerebrovascular interventions--covering aortic valve, mitral valve, tricuspid valve, surgical accessories, and diseases related to hemorrhage, ischemia and pathways in cerebrovascular intervention. It has built a relatively comprehensive array of product and solution portfolios in the field of structural heart disease and cerebrovascular interventions for use throughout China.

Key Points: 
  • Dr. Kar currently serves as the Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Health System, and Professor of Medicine at the David Geffen School of Medicine at UCLA.
  • He is recognized as the leading physician in developing and implementing minimally-invasive techniques in structural heart disease interventions.
  • Dr. Kar receives research grants from and is a consultant to multinational companies, such as Boston Scientific Corporation, Gore & Associates, and Abbott Vascular.
  • Peijia Medical was founded in 2012 and its headquarter is based in Suzhou,Jiangsu Province,China.

R3 Vascular Reports the Initiation of Its First-In-Human Clinical Study

Thursday, September 2, 2021 - 9:42pm

R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.

Key Points: 
  • R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.
  • The R3 Vascular platform incorporates an innovative scaffold design and bioresorbable polymer technology resulting in biomechanical performance comparable to metallic stents.
  • At a 98-micron strut thickness across all its usable range of diameters, the MAGNITUDE BRS device is the thinnest BRS ever tested in this clinical setting.
  • Given the dire and unmet clinical need of patients presenting with CLI undergoing BTK revascularization, we are extremely pleased by the rapid progression of our program, said R3 Vascular CEO Kamal Ramzipoor .